Bacterialized tumor cells as vaccine

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Whole-tumor cell vaccines (WTCVs) show promise in cancer immunotherapy but suffer from limited immunogenicity.
• Enhancing the immune response is crucial for effective cancer treatment.

Purpose of the Study:

• To develop a novel bacterialized tumor cell vaccine (BTC) to overcome the limitations of WTCVs.
• To evaluate the immunogenicity and anti-tumor efficacy of BTC vaccines in preclinical models.

Main Methods:

• Developed BTC vaccines by coating tumor cells with bacterial lysates.
• Assessed BTC vaccine effects on dendritic cell (DC) function, immune cell migration, and tumor microenvironment modulation in vitro and in vivo.
• Evaluated anti-tumor effects in five syngeneic murine tumor models, including combination therapy with anti-PD-1.

Main Results:

• BTCs enhanced DC phagocytosis, maturation, and antigen cross-presentation.
• BTC vaccination promoted tumor-specific CD8+ T cell expansion and memory formation while reducing exhaustion.
• BTCs demonstrated robust anti-tumor immunity, suppressed tumor growth and metastasis, and reversed the immunosuppressive tumor microenvironment.
• Combination therapy with anti-PD-1 showed synergistic anti-tumor effects.

Conclusions:

• BTC vaccines represent a safe and effective novel WTCV candidate.
• BTCs have strong potential for clinical translation in cancer immunotherapy.
• Bacterialization of tumor cells is a promising strategy to enhance vaccine immunogenicity and efficacy.